Found: 11
Select item for more details and to access through your institution.
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2013, v. 68, n. 1, p. 200
- By:
- Publication type:
- Article
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 64, n. 2, p. 398
- By:
- Publication type:
- Article
Darunavir-based dual therapy in HIV experienced patients.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19782
- By:
- Publication type:
- Article
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
- Published in:
- Journal of Medical Virology, 2014, v. 86, n. 10, p. 1648, doi. 10.1002/jmv.24017
- By:
- Publication type:
- Article
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.
- Published in:
- Journal of Medical Virology, 2011, v. 83, n. 3, p. 391, doi. 10.1002/jmv.21989
- By:
- Publication type:
- Article
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.
- Published in:
- Infection, 2016, v. 44, n. 5, p. 589, doi. 10.1007/s15010-016-0893-z
- By:
- Publication type:
- Article
Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.
- Published in:
- Infection, 2015, v. 43, n. 3, p. 339, doi. 10.1007/s15010-015-0764-z
- By:
- Publication type:
- Article
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study.
- Published in:
- Journal of Infectious Diseases, 2014, v. 210, n. 3, p. 354, doi. 10.1093/infdis/jiu051
- By:
- Publication type:
- Article
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen.
- Published in:
- BMC Medical Informatics & Decision Making, 2011, v. 11, n. 1, p. 40, doi. 10.1186/1472-6947-11-40
- By:
- Publication type:
- Article
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.
- Published in:
- Infection & Drug Resistance, 2018, v. 11, p. 615, doi. 10.2147/IDR.S152090
- By:
- Publication type:
- Article